Results 81 to 90 of about 11,641 (246)

Chronic Drug-Induced Liver Injury: Updates and Future Challenges

Frontiers in Pharmacology, 2021
Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing ...
Qiaoling Wang, Qiaoling Wang, Ang Huang, Jia-Bo Wang, Jia-Bo Wang, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +1 more source

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study [PDF]

, 2015
BACKGROUND & AIMS: The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study.
Barnhart, Huiman, Bonkovsky, Herbert L, Chalasani, Naga, Fontana, Robert, Gu, Jiezhun, Lee, William, Navarro, Victor, Reddy, K Rajendar, Serrano, Jose, Stolz, Andrew, Talwalkar, Jayant, United States Drug Induced Liver Injury Network, Watkins, Paul B   +12 more
core   +1 more source

Bacteroides fragilis 839 ameliorates anti-tuberculosis drugs-induced liver injury by suppressing inflammation and regulating gut microbiota in mice

Frontiers in Medicine
Anti-tuberculosis drug-induced liver injury (ATB-DILI), caused by first-line anti-tuberculosis (anti-TB) drugs, disrupts treatment and increases the risk of drug resistance.
Qiujuan Li, Chenbing Wu, Kangshuai Zhang, Ziyi Zhou, Jing Li, Jie Bai, Jun Cao, Xiaoxia Shi   +7 more
doaj   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source

Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. [PDF]

, 2014
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.A workshop was convened to discuss best practices
Andrade, Raul J, Avigan, Mark I, Bjornsson, Einar S, Cooper, Charles, Lewis, James H, Merz, Michael, Pasanen, Markku, Watkins, Paul B   +7 more
core   +2 more sources

Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic

Revista Española de Enfermedades Digestivas, 2015
Ciprofloxacin and amoxicillin/clavulanic are two widely used antibiotics due to their high efficacy and few side effects. While the percentage of hepatotoxicity of these antibiotics is low, their frequent use has led to a progressive increase in the number of cases.
Jordi Sánchez-Delgado, Mireia Miquel, Luís Moreno, Mercedes Vergara, Blai Dalmau, Meritxell Casas   +5 more
openaire   +3 more sources

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

British Journal of Clinical Pharmacology, EarlyView.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong, O Seong Kweon, Young‐Ran Yoon, Yu Kyung Kim, Yoo Na Kang, Se Young Jang   +5 more
wiley   +1 more source

The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use

Case Reports in Gastroenterology, 2016
Drug-induced liver injury (DILI) presents as a broad spectrum of adverse drug reactions which can range from a mild elevation in liver enzymes to fulminant liver failure.
Elena Cabb, Shanna Baltar, David Wes Powers, Karthik Mohan, Antonio Martinez, Eric Pitts   +5 more
doaj   +1 more source

Flavonoid Profile, Biological Potentials, and In Silico Approaches of Methanol Extracts on AChE: Amaranthus retroflexus L.

Chemistry &Biodiversity, EarlyView.
ABSTRACT This study investigated the flavonoid compounds and their biological activities in methanol extracts obtained from root, stem, leaf, and flower parts of Amaranthus retroflexus L. Flavonoids in the extracts were characterized for the first time by liquid chromatography–highresolution mass spectrometry (LC–HRMS), and a total of eight flavonoid ...
Bedrettin Selvi, Güler Durmuş, Mustafa Ceylan, Şuheda Yıldırım, Ümit M. Koçyiğit, Ümit Yırtıcı, Volkan Eyüpoğlu   +6 more
wiley   +1 more source

Drug-induced liver injury [PDF]

, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)Drug-induced liver injury (DILI) is a well known adverse reaction of many drugs. Direct toxic liver damage is associated with paracetamol toxicity
Einar S. Björnsson
core